Comments on: Rethinking Schering http://www.thecornerofficeblog.com/2008/05/01/rethinking-schering/ An entrepreneurs thoughts on business, personal finance and investing. Thu, 09 Jun 2011 19:02:59 -0700 http://wordpress.org/?v=2.8.6 hourly 1 By: Grant http://www.thecornerofficeblog.com/2008/05/01/rethinking-schering/comment-page-1/#comment-31934 Grant Tue, 20 May 2008 22:44:21 +0000 http://www.thecornerofficeblog.com/?p=797#comment-31934 That acquisition is a done deal. Intervet is (or was) a subsidiary of Organon BioSciences. That acquisition is a done deal. Intervet is (or was) a subsidiary of Organon BioSciences.

]]> By: MJ http://www.thecornerofficeblog.com/2008/05/01/rethinking-schering/comment-page-1/#comment-31925 MJ Tue, 20 May 2008 19:19:25 +0000 http://www.thecornerofficeblog.com/?p=797#comment-31925 Interesting fact about Schering-Plough is that they are in the middle of acquiring Intervet, an animal drug company. Interesting fact about Schering-Plough is that they are in the middle of acquiring Intervet, an animal drug company.

]]> By: MJ http://www.thecornerofficeblog.com/2008/05/01/rethinking-schering/comment-page-1/#comment-31510 MJ Fri, 02 May 2008 11:17:04 +0000 http://www.thecornerofficeblog.com/?p=797#comment-31510 I don't know Grant if I would invest in Pharma for a while. That sector is like a big hit or big miss stock selection. Nervous investors rule that sector. If they have something great, investors raise the stock big time, but at the first hint of bad news the stock tumbles even bigger. Even good companies like Merck, which has a spread out protfolio of drugs, gets hammered everytime bad news comes on a single drug even if it is doing well with other drugs. I stay out of Pharma for those reasons. Of course the potential could be huge if a company comes up with the next widely used drug. I don’t know Grant if I would invest in Pharma for a while. That sector is like a big hit or big miss stock selection. Nervous investors rule that sector. If they have something great, investors raise the stock big time, but at the first hint of bad news the stock tumbles even bigger. Even good companies like Merck, which has a spread out protfolio of drugs, gets hammered everytime bad news comes on a single drug even if it is doing well with other drugs.

I stay out of Pharma for those reasons. Of course the potential could be huge if a company comes up with the next widely used drug.

]]>